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ABSTRACT
Background Diagnostic delay results in relatively high
mortality among children with retinoblastoma in
Uganda, where treatment was limited to surgery and, for
some, radiotherapy. In order to improve outcomes, a
simple programme of neoadjuvant and adjuvant
chemotherapy was introduced. Here we report survival
before and after this change to medical practice.
Methods Affordable standard off-patent chemotherapy
agents were administered by trained paramedical staff to
groups of patients at the same time. Survival before and
after the introduction of chemotherapy was monitored.
Between 2006 and 2013 a total of 270 patients with
retinoblastoma were included, 181 treated prior to
chemotherapy and 89 after (beginning in 2009). We had
94% follow-up and 249 had histological veriﬁcation of
diagnosis.
Results Using a proportional hazards model adjusted
for age, sex and laterality, children treated after
chemotherapy was introduced had a 37% lower risk of
dying (HR 0.63, 95% CI 0.41 to 0.99) compared with
children treated before. Prior to the introduction of
chemotherapy only 15% of children who survived
bilateral disease retained vision after treatment compared
with 71% after chemotherapy.
Conclusions The introduction of chemotherapy proved
safe and cost-effective in non-specialist hands and was
associated with signiﬁcant improvements in survival and,
among bilateral cases, in preserving vision.
INTRODUCTION
An estimated 250 000 cancers are diagnosed each
year among children under the age of 15 years of
which only about 20–30%, mainly those living in
high income countries, receive adequate diagnostic
evaluation and care.1 Advances in paediatric oncol-
ogy have resulted in dramatic improvements in sur-
vival in some countries, but much of this remains
unavailable to patients in resource-constrained set-
tings. For example, in western Europe and the
USA, around 80% of children with cancer now
survive compared with <25% in low and middle
income countries (LMIC), notably those in
sub-Saharan Africa.2 A combination of many
factors have an impact on survival in LMIC, includ-
ing diagnostic delays resulting in advanced stage of
disease at presentation, lack of availability of che-
motherapeutic agents, cost of treatment leading to
abandonment of care and limited access to surgery
and radiotherapy.1 2
For example, childhood eye cancer retinoblast-
oma is largely curable in high income settings.3 4
Usually diagnosed at an early stage, modern treat-
ment can even avoid complete loss of vision in an
affected eye. However, the situation is markedly
different in sub-Saharan Africa.5 Until recently,
surgery had been the only treatment option avail-
able in Uganda, with a minority of children receiv-
ing radiotherapy from the country’s only
radiotherapy machine. In our recent nationwide
study in which we documented current treatment
practice, histology and survival for 282 children
with retinoblastoma, it was evident that mortality
rates were unacceptably high, largely because chil-
dren present with late stage disease.6 Survival at
36 months was only 44% overall, with most cases
being International Classiﬁcation of Retinoblastoma
(ICRB) group E, or already extraocular, at
diagnosis.
With the aim of improving survival from this
cancer we introduced a pragmatic programme of
neoadjuvant and adjuvant chemotherapy in one
referral centre in south-western Uganda. Here we
describe that programme, which was designed spe-
ciﬁcally for LMIC settings, and document improve-
ments in survival that followed.
METHODS
The efﬁcacy of chemotherapy was assessed within
the context of a clinical cohort of patients with ret-
inoblastoma described in detail elsewhere.6
Between January 2006 and December 2010,
ophthalmologists in Uganda were invited to enter
cases into the study while retaining management.
Some ophthalmologists in Uganda run mobile out-
reach teams, so cases came from all over the
country; the degree of clinical investigation varied
widely.6 At one centre (Ruharo Eye Hospital in
Mbarara), recruitment continued throughout 2011.
A standard form documented demography, clinical
features, treatment and follow-up. Staging was
according to the ICRB. Counsellors, using vernacu-
lar, gave information about the disease, its treat-
ment and the study, and parents signed or
thumb-printed that they understood and consented.
Some patients received radiotherapy at Mulago
Hospital, Kampala with the country’s only machine
(cobalt 60; dose 39 Gy in 13 fractions). A few
patients with metastasis were referred to the
Uganda Cancer Institute for late chemotherapy.
It became evident that mortality was unaccept-
ably high, with a signiﬁcant proportion of cases
having extraocular spread at presentation and the
use of chemotherapy was clearly indicated.
Therefore, a clinical decision was made to intro-
duce a pragmatic programme of neoadjuvant
chemotherapy (not previously available in Uganda)
within the framework of ongoing ethically
approved research. The programme had four key
features:
1. Affordable standard off-patent chemotherapy
agents were used.
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2. The drugs were administered by appropriately trained para-
medical staff (with cover from an experienced paediatrician)
in order to keep costs down and to allow a non-specialist
centre to provide care.
3. Children did not stay in hospital for the entire period of
their chemotherapy but the cost of transport and food was
provided for the child and carer during periods of treat-
ment. This had the effect of reducing abandonment of
care by parents who ﬁnd a prolonged hospital stay impos-
sible because of other family commitments. Between treat-
ments, use was made of mobile telephones and home
visits where necessary (with a home visiting team) to
maintain contact.
4. Chemotherapy treatment was provided to groups of patients
at the same time. This had the advantage of allowing parents
to beneﬁt from peer support and also it reduced abandon-
ment of care since parents of newly diagnosed children
could see beneﬁts for those further into treatment.
After 4 years of nationwide study and evident poor survival,
an amendment to the ethical approval was sought to allow
intensive follow-up of children provided with chemotherapy at
Ruharo Eye Hospital, Mbarara, in south-western Uganda and
additional informed consent was obtained. The protocol
involved neoadjuvant chemoreduction using a standard chemo-
therapy protocol used routinely in the UK and elsewhere.7
There was no doubt that changes to management were required
in order to improve outcomes and that chemotherapy was indi-
cated. Our aim was to assess safety when given by non-specia-
lists in an environment with high background child mortality
rates and prevalence of infectious disease. This activity was sup-
ported by paediatric oncology and paediatric ophthalmology
specialists from Leeds Teaching Hospitals, UK. The programme
used vincristine 1.5 mg/m2, carboplatin 600 mg/m2 and etopo-
side 300 mg/m2 (reduced below 1 year or 10 kg) intravenously
by peripheral veins. Two courses were given before surgery, con-
tinuing up to six according to histology (occasionally more)
with 21–28 days between. Blood was checked before each
administration, proceeding provided haemoglobin was >70 g/L,
platelets 100×103/μL and neutrophils 1×103/μL. Prophylaxis
was given throughout for bacterial infection (ciproﬂoxacin) and
malaria (meﬂoquine and bed nets) plus folic acid.
The ﬁrst case was treated in June 2009 and the tenth in
December 2009, without incident. It was therefore decided to
continue chemotherapy as standard best practice, preferably
starting before enucleation and with intensive follow-up of all
patients. All programme costs including chemotherapy, surgery,
transport and food were paid by donors.
Survival of patients was initially described using Kaplan–Meier
plots. A comparison of survival was made between the periods
before and after the introduction of chemotherapy; a randomised
trial is unethical in such situations since chemotherapy, once avail-
able, was indicated for almost all cases. Survival in the two time
periods was compared using a proportional hazards regression
model adjusting for age at diagnosis, sex and tumour extent at
diagnosis. Appropriate tests of the proportional hazards assump-
tion were carried out. Active follow-up of 270 of the 282 patients
in the clinical cohort up to June 2013 is presented here and
remains ongoing. Twelve patients are not included because they
died before treatment of any kind could be started (ﬁve patients),
had missing survival information (one patient) or due to recur-
rence (or disclosure) of a primary tumour in the previously
unaffected eye thereby receiving treatment in both time periods
(six patients).
RESULTS
A total of 270 children with retinoblastoma participated in the
study, 181 treated prior to the introduction of chemotherapy
and 89 treated after its introduction (ﬁgure 1). We achieved
94% follow-up of cases and 249 had histological veriﬁcation of
diagnosis; 68 children (25%) had bilateral disease. On the basis
of attendance at Ruharo Eye Hospital, 70 of 89 children in the
latter time period received chemotherapy during initial manage-
ment. Of those, all were group E or extracoular at diagnosis
except for two patients who were group C; all were HIV nega-
tive. Among the 181 children treated prior to chemotherapy
becoming available, 82 (45%) were alive after 24 months of
follow-up compared with 58/89 (65%) children treated after
chemotherapy became available (ﬁgure 1).
Survival was improved among children treated after chemother-
apy was available (ﬁgure 2); these children had a 37% lower risk
of dying (HR 0.63, 95% CI 0.41 to 0.99) compared with children
treated before chemotherapy became available. Age at diagnosis,
sex and laterality did not have a statistically signiﬁcant impact on
survival. However, extent of the tumour did have an impact on
survival, with children with extraocular involvement having an
increased risk of dying (HR 4.6, 95% CI 2.8 to 7.8) compared
with those with intraocular involvement only. Although the impact
of chemotherapy on survival among children with extraocular
involvement might be greater than in those with only intraocular
involvement, there is as yet limited evidence of this since conﬁ-
dence limits overlap (ﬁgure 2B). Case mix in terms of laterality did
not differ between patients treated before and after chemotherapy
became available (p=0.47), but there was a higher proportion of
cases with undetermined extent in the children treated before the
availability of chemotherapy (p<0.0001). Furthermore, among
children who survived with bilateral disease, the introduction of
chemotherapy was associated with an increase in the number in
whom some vision was saved (ﬁgure 3). Overall, 3 of 13 (77%)
Figure 1 Summary of survival to 24 months after treatment for all children demonstrating an improvement in the post-chemotherapy era compared
with the pre-chemotherapy era. Of the 89 children treated after chemotherapy was introduced, 70 received the drugs and 19 had surgery only. The
case mix was similar for both periods.
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survivors with bilateral disease had sight after chemotherapy com-
pared with 3 of 20 (15%) without chemotherapy.
A total of 324 courses of chemotherapy were given. Three
were delayed by low blood counts; one case required a blood
transfusion. Side effects were minor, mostly vomiting for 1 or
2 days which was controlled with oral metoclopramide and
dexamethasone intravenously 1 mg/kg at the start and end of
chemotherapy. One small vincristine extravasation resolved
uneventfully and two developed mild urticaria in their last
courses. One child twice had fever causing convulsion. One
child died 20 days after chemotherapy, the only death in which
leucopenia could be causal (see details below).
For many children included in the study the precise mode of
death is uncertain since the study was nationwide. Orbital fun-
gation was common in patients without radiotherapy but there
was only one known case after radiotherapy, so it was palliative.
The common sites of metastasis were the skull or spine with
paraplegia. There was one known hepatic metastasis and one to
local lymph nodes. One bilateral heritable case died with
primary sarcoma of the femur. Five children died in remission
after short febrile illnesses, apparently unrelated infections.
However, mode of death is known for the 20 chemotherapy
cases. Fifteen had extraocular extension (seven with macro-
scopic orbital tumour) and most died with apparent intracranial
extension following headache, convulsions or unconsciousness.
Of the ﬁve who were still intraocular, an 8-month-old child died
at home 20 days after the ﬁrst course following 2 days of cough.
This was the only death in which leucopenia from chemother-
apy might have resulted in an infection, all others being later.
Two patients reportedly died while on treatment for malaria
after prophylaxis had ended, one in remission and one after
chemoreduction but delayed enucleation. One had loss of
Figure 2 Kaplan–Meier survival estimates (with 95% conﬁdence limits) for children with retinoblastoma stratiﬁed by whether the child was treated
before or after the availability of chemotherapy for (A) all children, (B) children with extraocular tumour extent and (C) for children with only
intraocular involvement. The treatment strata did not differ among children with intraocular involvement only (p=0.33) but there was evidence of
divergence between the treatment strata among children with extraocular involvement (p=0.06). There was, however, no signiﬁcant interaction
between the effects of these factors in the proportional hazards regression analysis. Extraocular extent: optic nerve or sclera involved or orbital
tumour present at diagnosis; either eye if bilateral. Intraocular extent: none of the above or optic disc visibly uninvolved; both eyes if bilateral. Era
Pre: children diagnosed and treated before chemotherapy was available; Era Post: children diagnosed and treated after chemotherapy was available
but not necessarily used for all children depending on attendance.
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consciousness and was treated for pyogenic and tuberculous
meningitis although lumbar puncture did not conﬁrm these; he
died after 3 weeks. Although unilateral and with uninvolved
nerve, intracranial features suggest pineal tumour in which case
he had an extraocular tumour. One infant with bilateral disease
died of socket recurrence and metastasis although both optic
nerves were reported to be uninvolved; this was the only case of
complete failure of chemotherapy.
DISCUSSION
Diagnostic delay results in relatively high mortality among chil-
dren with retinoblastoma in Uganda; nearly half of tumours
were already extraocular at the time of diagnosis. The introduc-
tion of neoadjuvant and adjuvant chemotherapy proved safe in
non-specialist hands and was associated with signiﬁcant
improvements in survival. In addition, the initiation of chemo-
therapy has improved survival and, among bilateral cases,
together with laser therapy and cryotherapy is helping to pre-
serve vision in the second affected eye.
Follow-up was nearly complete with home visiting and
mobile telephones (92%; median 35 months for survivors). This
contrasts with other African series and allows ﬁrm conclusions
about outcome. Also, in striking contrast to Western countries,
it conﬁrmed high mortality.3 4 This was expected with extraocu-
lar extension but high mortality when the disease still intraocu-
lar (as far as could be assessed from limited histology) was one
reason for the introduction of chemotherapy.6 Survival curves
show substantial improvement with chemotherapy although
mortality is still very high with extraocular extension, mostly
because of intracranial involvement. The comparison group pre-
ceded chemotherapy so is in that sense historical, but the case
mix was similar and it was within the study period so marked
bias is unlikely. The use of historical comparison is inevitable
for assessing the impact of chemotherapy as improved survival
precludes randomised comparison.
It became clear during the study that chemotherapy was
essential for reducing mortality. To become widely available in
Africa it cannot be conﬁned to specialists in university hospitals
which currently exist in only three places in the East African
Community. It must be done by or with ophthalmologists to
manage the surgery, cryotherapy and laser. Therefore, to study
its safety by non-specialists, ethical approval was obtained for
10 cases at Ruharo Eye Hospital, supported by the Leeds team
using their protocol and an onsite paediatrician. Treatment
usually comprised six courses, occasionally with more to save
the second eye, since toxicity is non-cumulative and fertility
undamaged.8 It was found to be safe and was extended to subse-
quent cases. Preoperative chemoreduction (two courses) was
preferred unless the eye was already enucleated or diagnosis was
in doubt. Enucleation was planned for all group E ﬁrst eyes in
accordance with guidelines for developing countries.9 There is
debate about preoperative versus postoperative chemotherapy,
but this study cannot address that.10 11 In the West it is used for
a minority of patients selected by detailed histology and anterior
segment ultrasound.12 13 However, such selection is not possible
in Uganda at present because (1) about half the cases are extrao-
cular at diagnosis so require chemotherapy; (2) a quarter are
bilateral so need it to conserve the second eye; and (3) even
apparent intraocular cases have substantial mortality (ﬁgure 2C),
presumably they already have disseminated micrometastatic
disease at which stage chemotherapy can be curable. Initial
chemotherapy is therefore currently required for almost all
cases. Selection may become possible when detailed histology
becomes available but, even then, correlation between histology
and outcome derives mostly from other continents so may not
apply in Africa.14–16
The side effects of chemotherapy were minimal and periph-
eral veins were adequate, sometimes using ketamine sedation for
cannulation. The interval between courses was 28 days, with the
child returning home between courses. Although it may be pref-
erable for the period to be shorter in order to limit tumour
escape, in this environment parents found this too pressing.
Retaining them in hospital throughout would be ideal in case
leucopenia caused infection, but home responsibilities make this
impractical and it would increase costs. The interval was moni-
tored by telephone contact and home visits (where necessary)
with few problems. Treating children together in the same
weeks produced a family atmosphere, giving parents peer
Figure 3 Survival at 24 months after treatment and sight preservation among children with bilateral retinoblastoma illustrating improved outcomes
in the post-chemotherapy era compared with the pre-chemotherapy era.
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support during stressful times and limiting drop-out. Starting
with chemoreduction enabled parents to interact with already
operated cases so that subsequent refusal of enucleation was
uncommon. Prosthetic eyes were important for parent satisfac-
tion and avoiding teasing at school. Ready-made prostheses gave
acceptable cosmetic results, although contracted sockets from
radiotherapy sometimes prevented this. Grafts of oral mucosa
are being used to enlarge sockets, and myoconjunctival socket
closure over implants has been introduced to improve prosthesis
mobility.17
Survival has improved since chemotherapy has become avail-
able. Deaths still occur despite chemotherapy but most had
extraocular extension, emphasising the need for parents not to
delay. Only one death occurred when leucopenia could have
been the cause. The near hopeless prognosis for orbital exten-
sion or recurrence (one of 72 surviving even after having
chemotherapy and radiotherapy) was disappointing and con-
trasts with other centres reporting better survival.16 This indi-
cates a need for introduction of other treatments such as
high-dose chemotherapy, brachytherapy or conformal radiother-
apy when these become practical.18 19 Surgical debulking of
orbital tumour was unnecessary because a few courses of
chemotherapy have the same effect and also give valuable palli-
ation for those in whom death occurs from metastases.
Mortality in children aged <5 years in Uganda is still substantial
(national data show it was 13.7% when our study started), so
some deaths were probably unrelated.20
For the ﬁrst time, among cases with bilateral tumour, more
eyes are being saved with good vision, thereby preventing blind-
ness. These conserved eyes need repeated examination under
anaesthesia with cryotherapy and laser treatment as necessary,
and so represent a signiﬁcant workload. The tumours can reacti-
vate even after 1 or 2 years, and cure of group D tumours in
this study is not yet assured.
In a secondary analysis we estimate that the average cost per
child, including food and transport, was around US$1000. A
formal cost-effectiveness analysis has not yet been performed
but the results indicate that chemotherapy is very likely to be
cost-effective, even in the most resource-constrained African
health systems. The 37% reduction in absolute risk of death
with chemotherapy indicates a cost per child saved of US$2703
($1000×(1/0.37)). Each surviving child could expect to live at
least another 40 healthy years21 which, following discounting at
3% per annum, would provide approximately 20 healthy years
in present value terms. Even ignoring the beneﬁts of sight pres-
ervation for surviving children who would otherwise be blind,
this would indicate a cost of US$135 per disability-adjusted life
year (DALY) averted ($2703/20), ranking it among the most
cost-effective interventions available for low-income countries.22
To provide context, the WHO has recently recommended use
of routine viral load testing for monitoring of patients on anti-
retroviral therapy at a cost of >US$4000 per DALY averted; this
is currently being made available in many countries.23 One
dollar of resources spent on chemotherapy would produce 30
times the health beneﬁts of a dollar spent on routine viral load
monitoring ($4000 vs $135). Thus, the costs of this interven-
tion are not prohibitive and it should be possible for health
systems to make it widely available.
In summary, the main obstacle to reducing mortality from ret-
inoblastoma in Uganda is delayed presentation, but chemother-
apy is signiﬁcantly improving survival and saving sight among
bilateral cases. It is safe in non-specialist hands and should be
made available in other centres. It is currently needed in this
environment for almost all cases and the ﬁnancial constraints
can be overcome. With a safe and effective treatment pro-
gramme in place, there is an urgent need in Uganda and other
countries in sub-Saharan Africa to address diagnostic delay with
national education campaigns encouraging people to come
forward with affected children earlier, but there is little point in
initiating such schemes in the absence of effective treatment. It
is important to note that the approach used here in relation to
chemotherapy is applicable to some other childhood cancers for
which mortality remains unacceptably high, in particular the
most common childhood cancer in Uganda and some other
parts of Africa—namely, Burkitt lymphoma.
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